SOUTH SAN FRANCISCO, Calif., Aug. 10, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter ending June 30, 2011 and provided an update on recent clinical and corporate progress.
